Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozone SCHEMBL6212962 | 0.90 | SOAT1 (0.35) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL918077 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL10405977 | 0.82 | ALDH1A1 (0.40) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL11106925 | 0.82 | ALDH1A1 (0.40) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL31693092 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL21129986 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL2738378 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19LMNAHSD17B10GAA | |
| SCHEMBL21130051 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL18465494 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 | |
| SCHEMBL356446 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2C19CYP3A4LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117203194-A | Novel compounds useful as STING agonists and uses thereof | 北京加科思新药研发有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2019-05-23 | — | — | US | disclosed |
| EP-3478676-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Orion Corporation (FI) | 2019-05-08 | — | — | EP | disclosed |
| WO-2018002437-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2018-01-04 | — | — | WO | disclosed |
| US-9242970-B2 | Lactam derivatives useful as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2638008-B1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| CN-103201261-A | Lactam derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2013-07-10 | — | — | CN | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| EP-2069312-A2 | PYRIDIZINONE DERIVATIVES | Cephalon, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008013838-A2 | PYRIDIZINONE DERIVATIVES | CEPHALON, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20060154930-A1 | Substituted amino heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-07-13 | — | — | US | disclosed |
| US-5536854-A | Preparation of 2-methyl-1,4-butanediol and 3-methyltetrahydrofuran | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-16 | — | — | US | disclosed |
| US-5530017-A | CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLAUCOMA | SMITHKLINE BEECHAM CORP (US) | 1996-06-25 | — | — | US | disclosed |
| US-5444080-A | Hypotensive agents | SMITHKLINE BEECHAM CORPORATION (US) | 1995-08-22 | — | — | US | disclosed |
| EP-0541705-A4 | SUBSTITUTED 1H-IMIDAZOL-5-YL)ALKANOIC ACIDS | — | 1993-11-10 | — | — | EP | disclosed |
| EP-0541705-A1 | SUBSTITUTED 1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002510-A1 | SUBSTITUTED [1H-IMIDAZOL-5-YL]ALKANOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| US-4346087-A | CORROSION RESISTANCE | TOHO CHEMICAL INDUSTRY CO., LTD. (JP) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154930-A1 | Substituted amino heterocycles as vr-1 antagonists for treating pain | OPRL1, OPRM1, OPRK1 | ALDH1A1 1626/4885CYP2C19 1869/4885CYP3A4 885/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 2282/4885CYP2C19 446/4885CYP3A4 987/4885 |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | TBXA2R, ADRA2C, ADRB2 | ALDH1A1 93/4885CYP2C19 167/4885CYP3A4 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.